Last reviewed · How we verify
ERAS-0015 in combination
At a glance
| Generic name | ERAS-0015 in combination |
|---|---|
| Also known as | Pembrolizumab, Keytruda, Panitumumab, Vectibix |
| Sponsor | Erasca, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ERAS-0015 in combination CI brief — competitive landscape report
- ERAS-0015 in combination updates RSS · CI watch RSS
- Erasca, Inc. portfolio CI